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Abstract
The annual incidence rate of cancer is estimated to be more than 11,000 patients in the 
U.K. in the age group of 15–40 years, which corresponds to 4% of all cancer patients. The 
diagnosis of cancer is followed by devastating consequences for the patients and their 
families in this age group. Although the treatment of cancer is of crucial significance, it 
should also examine the impact of the disease on fertility at the time of the diagnosis 
and the damages caused from the surgical treatment, chemotherapy, or radiotherapy. 
The gynecological cancer, especially the diagnosis of ovarian cancer, the prevention, and 
treatment, as well as the fertility preservation in young women, represent the gold stan-
dard for all gynecologists. The crucial disadvantage remains the difficulty in primary 
diagnosis of ovarian cancer and the coexistence with pregnancy, focusing on the fertil-
ity preservation and maintaining pregnancy. In the absence of large perspective ran-
domized trials and cohort studies, the therapeutic mapping and optimal management 
of these patients are difficult. In order to establish detailed guidelines, it is necessary to 
ensure surgical mapping depending on the cancer staging and the quality of life of the 
patients.
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1. Introduction
The presence of adnexal masses during pregnancy consists of a less rare condition. With the 
help and increase of the transvaginal ultrasound, the diagnosis of adnexal masses or cysts 
becomes more frequent. The incidence of these masses during pregnancy is estimated to be 
0.2–2% depending on the week of gestation. The malignancy rate consisted of 1–6%, leaving 
the vast majority in benign level [1].
Distinguishing between malignant and nonmalignant adnexal masses or cysts especially dur-
ing pregnancy depends on the level experience of the gynecologist and the disease staging. 
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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The most common nonmalignant cyst represents the functional cysts. These cysts or presence 
of corpus luteum are harmonically influenced and depict different ultrasound morphology. 
Imaging findings consist of thin wall without disturbance of architecture and lack of vascu-
larization (Figure 1) [2].
These functional cysts can be shortly or after a couple of months absorbed. The appearance of 
adnexal mass or cyst during early pregnancy must lead to differential diagnosis of an ectopic 
pregnancy. Other examples such as cystadenomas or dermoid cysts during pregnancy can be 
removed laparoscopically during the first trimester.
The evaluation of an adnexal mass and the differential diagnosis toward a possible adnexal 
malignancy can be managed with ultrasound examination, abdominal MRI, and tumor markers.
Ultrasound examination can easily be undergone and consists of routine procedure with 
increased sensitivity and specificity, respectively. Imaging findings can facilitate the differen-
tial diagnosis between a malignant and a benign adnexal disease.
Ovarian cancer associated with pregnancy represents a rare entity. Ultrasound examination can 
depict tumor morphology, tumor size, papillary protrusions, and color Doppler flow (Figure 2) [3].
The mentioned ultrasound imaging clearly depicts the presence of color Doppler as indirect 
sign of malignant vascularization, presence of papillary protrusions inside the adnexal wall, 
and disturbance of adnexal architecture. All these ultrasound characteristics indicate the pres-
ence of ovarian cancer [4].
Figure 1. A simple ovarian cyst on the right side of the uterus fulfilling all the characteristics mentioned before (Professor 
Ahmed Abdel Gadir. Illustrated Gynecology and Infertility Ultrasound).
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The use of MRI safely during second or third trimester of gestation increases, accompanied 
with the ultrasound imaging findings, the sensitivity and specificity of diagnosing ovarian 
cancer during pregnancy. Diagnostic keys during abdominal MRI can be tumor invasion or 
spread, lymphatic spread, disease staging, and possible metastatic lesions [5].
Classic imaging findings of adnexal malignancy consist of necrotic or solid elements 
inside the ovarian wall, septal thickening, or mural nodules and papillary excrescences 
(Figure 3) [6].
The use of tumor markers in cases of adnexal masses or cysts often accompanied with 
pregnancy remains a controversial entity. Due to daily physiologic and hormonal changes 
during pregnancy, all tumor markers are increased. Ca-125, a tumor marker capable of 
distinguishing a benign from a malignant adnexal mass, is often increased during preg-
nancy [7].
Other tumor markers, such as alpha fetoprotein (AFP) and b-HCG often increased in germ 
cell tumors or Inhibine B and anti-mullerein protein (AMH) often increased in granulosa-
associated tumors, are equally increased during all trimesters of gestation [8].
Additionally, elevated Ca-125 levels were found in cases of acute pelvic inflammatory disease 
(PID). Many current studies have been conducted assuming the presence of the mentioned 
tumor marker in the fallopian tubes [9].
Generally, tumor markers are not used as a screening test. From their point of view, they con-
tribute indirectly toward the final diagnosis. The therapeutic mapping consists of the assidu-
ous physical examination, the imaging findings, and the ranges of the laboratory examination. 
Ultimate goal remains the quality of life regarding the mother and the fetus.
Figure 2. Primary invasive ovarian epithelial cancers. (A) Stage 1, clear cell carcinoma of the ovary. (B) Unilocular solid 
early invasive cancer with increased vascularity on color Doppler.




According to current literature and long conductive series, the frequency of adnexal masses 
during pregnancy is estimated to be 1 in 81 to 1 in 2500 live births [10].
On the other side, the incidence of ovarian carcinoma in correlation to pregnancy is estimated 
to be 1 in 21,500 (Figure 4) [11].
The therapeutic mapping regarding the presence of ovarian carcinoma depends on the pre-
disposition factors, such as the tumor size, tumor staging, lymphatic infiltration, tumor inva-
sion, and presence of metastatic lesions such as liver, brain, and bone metastasis.
The ultimate goal remains the cytoreduction or better debulking. In other words, peritoneal 
washing, total hysterectomy, bilateral salpigoopherectomy, pelvic and paraortic lymph node 
dissection, inspection of all peritoneal surfaces and multiple biopsies, and finally, omentum 
dissection.
There are nonspecific clinical signs to primarily diagnose the existence of ovarian cancer 
(Figure 5).
For advanced stages of ovarian cancer, the optimal treatment consists of combination of che-
motherapy and radiotherapy (Figure 6) [12].
Figure 3. A 34-year-old pregnant woman. (A) Axial RARE T2-weighted MR image obtained at 23 weeks’ gestation shows 
bilateral solid adnexal masses (arrows). (B) Axial RARE T2-weighted MR image through upper abdomen shows large 
tumor deposit (arrow) abutting liver. Appearances are considered indicative of malignancy. Cesarean hysterectomy and 
bilateral salpingo oophorectomy were performed at 28 weeks’ gestation because of progression of subphrenic tumor 
with diaphragmatic irritation. Pathology results showed benign metastasizing leiomyoma. Masses spontaneously 
regressed after surgery and patient remains free of disease 3 years after surgery.
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Figure 4. Ovarian cancer classification. Source: NCCN Guidelines 2016.
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The most significant issue remains the therapeutic mapping regarding the combination of 
ovarian cancer and pregnancy.
As we mentioned above, primary goal represents the increase of free survival rate and quality 
of life of the mother and fetus, respectively (Figure 7).
The incidence of ovarian cancer is increased in older pregnant women [13]. In other words, 
age represents a predispositional factor which influences the pregnancy outcome.
Many studies from the current literature suggested that many histologic types of ovarian 
cancer in pregnant women are similar to those in nonpregnant women [14]. Surgical dissec-
tion of an adnexal mass diagnosed during pregnancy remains a controversial issue. Adnexal 
mass with diameter larger than 6 cm, with peripheral vascularization, ascites, or persistent 
presence of more than 4 months, requires surgical dissection and histologic confirmation and 
exclusion of potential malignancy [15].
Generally, the ultimate treatment of ovarian cancer during pregnancy consists of surgical inter-
vention with adequate staging. For advanced stages, stages with metastatic lesions, the current 
literature, and the standard guidelines recommend treatment similar to nonpregnant women—
surgical debulking combined with series of chemotherapy or radiotherapy (Figure 8).
As we mentioned above, the standard treatment of epithelial ovarian cancer (EOC), the his-
tologic type with the worst prognosis, consists of total hysterectomy, bilateral salpigoopher-
ectomy, peritoneal washing, dissection of the omentum, dissection of all peritoneal implants, 
and most of all lymph node dissection (pelvic and paraaortic).
If all imaging findings and the laboratory report advocate of an early-stage lesion, the thera-
peutic mapping is focusing on unilateral oophorectomy or adnexectomy with appropriate 
staging. It is very important to keep in mind all conservative surgical methods focusing on 
the pregnancy maintenance.
Figure 5. Symptoms and clinical signs of ovarian cancer.
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In cases of advanced stages, termination of pregnancy and use of noeadjuvant chemotherapy 
or radiotherapy is recommended.
When series of chemotherapy are mandatory regarding advanced stages of ovarian cancer, 
the suitable period is during the second or third trimester, avoiding the organogenesis of 
Figure 6. Chemotherapy in ovarian cancer.
Ovarian Cancer and Pregnancy
http://dx.doi.org/10.5772/intechopen.70155
91
first trimester, period with increased incidence of genital malformations. During these 
trimesters, the risk of genital malformations does not exceed the risk of general popula-
tion [16].
Additionally, for patients with diagnosed ovarian cancer during pregnancy and focusing 
on the current guidelines platinum-based chemotherapy, combination of carboplatin with 
weekly paclitaxel is strongly recommended after the first trimester, representing a safe che-
motherapeutic procedure [17].
Radiotherapy is recommended in advanced stages alone or in combination with series of che-
motherapy. The current literature and the global guidelines strongly advise doses of radio-
therapy as in nonpregnant women.
Radiotherapy is restricted in cases of dysgerminoma as an example of the most common 
germ cell tumor due to its radiosensitivity. The field of exposure extends from T11 to L5, with 
shielding of the contralateral ovary and the femur head [18].
Figure 7. Relative 5-year survival for invasive epithelial ovarian cancer. Source: Wikipedia.
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Figure 8. Types of hysterectomy. Source: Cancer.org.




Therapeutic mapping of ovarian cancer during pregnancy remains a controversial issue. 
Many studies have been conducted in order to establish safe guidelines of treatment with 
the ultimate goal of increasing free survival and quality of life of the mother and the fetus. 
Primary diagnosis, multidisciplinary cooperation, assiduous imaging findings, and labora-
tory examinations assure proper treatment.
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